An interventional study of Probiotics and Placebo in Gestational Diabetes Mellitus (GDM), sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Women's Hospital School Of Medicine Zhejiang University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.
Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 15th largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2023, is one of 36 with no phase, reaches primary completion later than 8 of the 22 other live ones, and was the 61st registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:
Yang ZHANG · Sites in China
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Peking University · Sites in China
Ages 18+ · Healthy volunteers
Peking Union Medical College Hospital · Sites in China
Ages 18+ · Women only
Peking Union Medical College Hospital · Sites in China
Ages 20–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 334 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 291 across the 39 interventional studies, 1,122 across the 29 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 68 has an industry lead sponsor. The 10 most frequent:
Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 80 studies on the registry; 50 are open to participants now.
Women's Hospital School Of Medicine Zhejiang University has 9 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234332Peking UniversityPeking University Birth Cohort in Weifang (PKUBC-WF) | 2026-12-31 |
| NCT07119177Yang ZHANGLong-term Evaluation of Gestational Endocrine & Metabolic Dynamics | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Diabetes, Gestational with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gut microbiota is instrumental in the microbial and metabolic network of pregnant women, and is potentially related with gestational diabetes. Perinatal probiotic intervention contributes to improved glucose regulation during pregnancy. Our randomized, double-centered, placebo-controlled study is planned to recruit 334 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly probiotic powder per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about neonatal weight will be registered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pregnant women who meet the high-risk indicators for GDM and agree to participate in this study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Probiotic powder 1 bag per day, as well as health guidance about diet and exercise. From recruitment until OGTT.
Dietary Supplement: Probiotics
Placebo 1 bag per day. Similar health guidance about diet and exercise. From recruitment until OGTT
Dietary Supplement: Placebo
Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid
placebo with similar appearance and smell but not containing probiotics
the incidence of gestational diabetes
The number of cases and incidence of gestational diabetes according to OGTT
Time frame: 24-28th weeks gestation
The incidence of macrosomia
macrosomia refers to a newborn weighs more than 4 kg)
Time frame: Delivery
Weight gain during pregnancy (kg)
Weight gain during pregnancy (kg) = Maternal weight at delivery - weight pre-pregnancy
Time frame: Delivery
Started Oct 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 24 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women's Hospital School Of Medicine Zhejiang University